首页> 外文OA文献 >PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy

【2h】

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy

机译：肿瘤细胞中的PD-L1（SP142）表达预测，血管内大型B细胞淋巴瘤患者预后差，基于RITUXIMAB的多蛋白化疗治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Yuka Suzuki; Kei Kohno; Kosei Matsue; Ayako Sakakibara; Eri Ishikawa; Satoko Shimada; Kazuyuki Shimada; Seiyo Mabuchi; Taishi Takahara; Seiichi Kato; Shigeo Nakamura; Akira Satou;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy [J] . Yuka Suzuki, Kei Kohno, Kosei Matsue, Cancer Medicine . 2020,第13期

机译：肿瘤细胞中的PD-L1（SP142）表达预测，血管内大型B细胞淋巴瘤患者预后差，基于RITUXIMAB的多蛋白化疗治疗
2. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation [J] . DOUGLAS A. STEWART, NIZAR BAHLIS, amp, Leukemia and lymphoma . 2009,第8期

机译：pY-STAT3和p53表达可预测高剂量化疗和自体干细胞移植治疗弥漫性大B细胞淋巴瘤的预后不良
3. Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD‐L1 and predicts poor prognosis in B‐cell lymphoma [J] . Xiaoxia Liu, Yanyu Zhang, Yi Han, Molecular oncology. . 2020,第5期

机译：GLT1D1的过度表达通过PD-L1的糖基化诱导免疫抑制，并预测B细胞淋巴瘤预后差
4. STAT3 PATHWAY IS UPREGULATED IN CANINE DIFFUSE LARGE B CELL LYMPHOMAS AND IS ASSOCIATED WITH A POOR PROGNOSIS [C] . Xuan Pan, Paulo Jark, Courtney Hong, Conference of the American^College^of^Veterinary^Internal^Medicine . 2016

机译：在犬弥漫性大B细胞淋巴瘤中，达斯3途径上调，并与预后差有关
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy [O] . Yuka Suzuki, Kei Kohno, Kosei Matsue, 2020

机译：PD-L1（SP142）在肿瘤细胞中的表达预示着以利妥昔单抗为基础的多药化疗的血管内大B细胞淋巴瘤患者的预后不良
7. High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy. [O] . Guang Yang, Xue-Jiao Wang, Li-Jun Huang, 2015

机译：高aBCG4表达与基于顺铂的化疗治疗的非小细胞肺癌患者预后不良有关。

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy

著录项

相似文献

相关主题

期刊订阅